Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

81.58 -1.58 (-1.90%)
Delayed Quote Updated: 12:17 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
LeMaitre Vascular (NASDAQ:LMAT): A Quality Stock for Long-Term Investors ↗
Via Chartmill
News headline image
1 of Wall Street’s Favorite Stocks to Own for Decades and 2 We Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
3 Small-Cap Stocks We Steer Clear Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
2 Profitable Stocks to Target This Week and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Supply Chain
News headline image
3 Out-of-Favor Stocks with Questionable Fundamentals
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether... 
Via StockStory
LeMaitre Vascular (NASDAQ:LMAT) Shares Slide on Q2 Earnings Miss ↗
Via Chartmill
LeMaitre Vascular Inc. (NASDAQ:LMAT) Passes the Quality Test with Caviar Cruise Screen ↗
Via Chartmill
LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests ↗
Via Chartmill
News headline image
Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - special... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
LeMaitre Vascular (LMAT) Q2 2026 Earnings Call Transcript ↗
Artegraft sales surged 34% as gross margins expanded to 72.1%. 
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From LeMaitre’s Q2 Earnings Call
LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and As... 
Via StockStory
Topics Earnings
LeMaitre Vascular (NASDAQ:LMAT) Reports Steady Q1 2026 Results with Earnings Beat and In-Line Revenue ↗
Via Chartmill
Topics Earnings
News headline image
Stocks making big moves yesterday: LeMaitre, ePlus, Booking, Paymentus, and Vishay Intertechnology
Check out the companies making headlines yesterday: LeMaitre (NASDAQ:LMAT): Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell by 18.6% on Wednesday... 
Via StockStory
Topics Earnings
News headline image
Why LeMaitre (LMAT) Shares Are Getting Obliterated Today
What Happened? Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 18.6% in the morning session after the company reported second-quarter r... 
Via StockStory
Topics Artificial Intelligence
News headline image
LMAT Q2 Deep Dive: International Growth and Supply Constraints Shape Results
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil... 
Via StockStory
News headline image
LeMaitre Vascular Q2 Earnings Call Highlights ↗
LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign... 
Via MarketBeat
Topics Earnings
News headline image
LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6%
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil... 
Via StockStory
News headline image
LeMaitre (LMAT) Reports Earnings Tomorrow: What To Expect
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know. LeM... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Energy
News headline image
1 High-Flying Stock to Target This Week and 2 Facing Headwinds
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory
Topics Initial Public Offering
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Find Risky
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
Topics Firearms
News headline image
3 of Wall Street’s Favorite Stocks We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Topics Electric Vehicles
News headline image
1 Reason to Avoid LMAT and 1 Stock to Buy Instead
LeMaitre has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15.5% to $101.53 ... 
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
News headline image
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, includ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
3 Healthcare Stocks with Open Questions
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
Topics Retirement
News headline image
5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns o... 
Via StockStory
Topics Earnings
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory
News headline image
LMAT Q1 Deep Dive: Artegraft Expansion and Pricing Drive, Margin Upside Meets Cautious Market
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio... 
Via StockStory
News headline image
LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio... 
Via StockStory
News headline image
LeMaitre (LMAT) Q1 Earnings Report Preview: What To Look For
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market hours. Here’s what you need to know. LeMaitre beat... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.